CD19 is the most widely used hematologic malignancy target in CAR-T cell therapy and good therapeutic effects have been achieved in clinical trials of hematological malignancies such as B-ALL, CLL, FL, DLBCL and MCL. Fluorescent conjugated CD19 proteins are reliable reagents for detection of CAR expression. This can simplify detection procedures and save detection time. We offer FITC and PE conjugated CD19 proteins. They are good tools for detection of anti-CD19 CAR expression in samples by flow cytometry.
|Catalogue No.||Product description||Species||Tag||Expression host||Size|
|11880-H08H-B||Biotinylated CD19 Protein||Human||His Tag||HEK293 Cells||20µg / custom size|
|Catalogue No.||Species||Tag||Expression host||Size|
|11880-H02H||Human||Fc Tag||HEK293 Cells||20µg / 50µg|
|11880-H08H||Human||His Tag||HEK293 Cells||20µg / 50µg|
|11880-H08B||Human||His Tag||Baculovirus-Insect Cells||20µg / 50µg|
|90051-C02H||Cynomolgus||Fc Tag||HEK293 Cells||20µg / 100µg|
|90051-C08H||Cynomolgus||His Tag||HEK293 Cells||20µg / 100µg|
|50510-M08H||Mouse||His Tag||HEK293 Cells||10µg / 20µg / 50µg|
In addition to CD19, molecules such as CD20, CD22, CD30, IL3RA are also hot targets for hematologic malignancies research, especially for CD19-negative hematologic malignancies.
We offer biotinylated proteins of the following targets. If you're interested in, please contact 400-890-9989.
|CD20||Leukemia, Lymphoma, Multiple myeloma|
|CD22 / Siglec-2||B-cell lymphoma|
|CD33 / Siglec-3||Myeloid malignancies|
|CD38||Acute myeloid leukemia, Multiple myeloma|
|CD5 / Leu-1||T cell acute lymphoblastic lymphoma|
|CD56||Acute myeloid leukemia|
|NKG2D ligand 1 / ULBP1||A variety of hematological malignancies|
|NKG2D ligand 2 / ULBP1||A variety of hematological malignancies|
|IL1R3||Chronic myeloid leukemia|
|ROR1||Non-small cell lung cancer, Breast cancer, Leukemia|
• De Oliveira, S. N., Wang, J., Ryan, C., Morrison, S. L., Kohn, D. B., & Hollis, R. P. (2013). A CD19/Fc fusion protein for detection of anti-CD19 chimeric antigen receptors. Journal of translational medicine, 11(1), 23.
• Zah, E., Lin, M. Y., Silva-Benedict, A., Jensen, M. C., & Chen, Y. Y. (2016). T cells expressing CD19/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells. Cancer immunology research, 4(6), 498-508.
• Maude, S. L., Teachey, D. T., Porter, D. L., & Grupp, S. A. (2015). CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood, 125(26), 4017-4023.